# Clinical Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patients With Refractory Cirrhotic Ascites

> **NCT06919523** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Mansoura University** · enrollment: 70 (estimated)

## Conditions studied

- Refractory Ascites

## Interventions

- **DRUG:** Dapagliflozin 5mg
- **DRUG:** Standard care treatment

## Key facts

- **NCT ID:** NCT06919523
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2025-08-15
- **Final completion:** 2025-09-15
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06919523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06919523, "Clinical Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patients With Refractory Cirrhotic Ascites". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06919523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*